News
-
-
PRESS RELEASE
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
Immunic, Inc. announces pricing of $5.1 million registered direct offering led by Aberdeen Investments for clinical pipeline of therapies. Funds to be used for clinical trials and operations -
-
-
-
-
-
PRESS RELEASE
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
Immunic presents key data on vidofludimus calcium at ACTRIMS Forum 2025, highlighting its potential in multiple sclerosis. Phase 2 CALLIPER trial results expected in April -
-
PRESS RELEASE
Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
Immunic's Oral IMU-856 shows dose-dependent increase of GLP-1 in celiac disease patients, potential as oral weight management treatment. New data presented in webcast
